Park Avenue Securities LLC Has $2.31 Million Stock Position in Novo Nordisk A/S $NVO

Park Avenue Securities LLC lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 30.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,335 shares of the company’s stock after selling 19,852 shares during the quarter. Park Avenue Securities LLC’s holdings in Novo Nordisk A/S were worth $2,307,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. Revolve Wealth Partners LLC grew its stake in shares of Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after purchasing an additional 200 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 21.0% in the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock valued at $4,312,000 after purchasing an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC raised its position in Novo Nordisk A/S by 18.2% in the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after purchasing an additional 1,587 shares during the last quarter. Nomura Asset Management Co. Ltd. bought a new position in Novo Nordisk A/S in the 2nd quarter worth approximately $405,000. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new position in Novo Nordisk A/S during the 2nd quarter worth $75,000. 11.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently commented on NVO. Deutsche Bank Aktiengesellschaft cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. CICC Research began coverage on Novo Nordisk A/S in a report on Friday, January 9th. They issued an “outperform” rating and a $73.50 price target on the stock. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Hold” and an average target price of $65.56.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA clears a higher-dose formulation of Wegovy, which can deepen Novo Nordisk’s obesity franchise and support sales/price power for its semaglutide lineup. FDA Clears NVO’s Higher Dose of Wegovy
• Positive Sentiment: Novo Nordisk launched a Phase 1 study of LX9851, an oral non‑incretin obesity candidate licensed from Lexicon, expanding the pipeline beyond injectable semaglutides and offering long‑term upside if oral assets succeed. Lexicon and Novo Nordisk Announce Phase 1
• Positive Sentiment: Ongoing share repurchase programme (part of up to DKK 15bn plan) supports EPS and signals management confidence, which can be a near‑term technical tailwind. Novo Nordisk A/S – share repurchase programme
• Neutral Sentiment: Analyst and valuation pieces are mixed: some highlight Novo’s entrenched market position and recent approvals, while others warn of slowing growth and competition—contributing to divergent investor views on valuation. Novo Nordisk Valuation Check As LX9851 Expands
• Negative Sentiment: Indian patent expiry has opened the floodgates: multiple Indian manufacturers launched low‑cost generics of Ozempic/Wegovy (semaglutide), cutting prices by ~70% locally and setting a precedent for aggressive generic competition in price‑sensitive markets. This raises long‑term pricing and volume risk outside core markets. Indian drugmakers flood market with cheaper versions
• Negative Sentiment: Multiple reports emphasize cheap generic launches in India and other local markets (coverage by CNBC, DrugStoreNews, Moby), underscoring immediate revenue pressure where patent protection has lapsed and the risk of parallel imports or international pricing pressure over time. India launching cheap weight-loss drugs

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $36.81 on Tuesday. The firm has a fifty day moving average of $47.76 and a two-hundred day moving average of $50.93. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The stock has a market capitalization of $164.36 billion, a price-to-earnings ratio of 10.61 and a beta of 0.73. Novo Nordisk A/S has a 52 week low of $35.85 and a 52 week high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. As a group, equities research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The business also recently announced a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. This represents a dividend yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s payout ratio is presently 52.74%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.